Results 61 to 70 of about 20,950 (257)

MPO-ANCA-Associated Necrotizing Glomerulonephritis in Rheumatoid Arthritis; a Case Report and Review of Literature [PDF]

, 2017
BACKGROUND: Renal involvement in rheumatoid arthritis (RA) is common and has a negative impact on patient survival. Only few cases have been reported of necrotizing glomerulonephritis (GN) associated with myeloperoxidase anti-neutrophil cytoplasmic ...
Carvalho, D, Carvalho, F, Góis, M, Messias, A, Nolasco, F, Sousa, H, Sousa, J   +6 more
core   +1 more source

Secukinumab in adult patients with lichen planus: Efficacy and safety results from the randomised, placebo-controlled, proof-of-concept PRELUDE study.

British Journal of Dermatology
BACKGROUND Patients with lichen planus (LP) refractory to available therapies often experience a high disease burden; representing a population with a clear unmet need for new treatments.
T. Passeron, M. Reinhardt, Benjamin D Ehst, Jonathan S. Weiss, J. Sluzevich, M. Sticherling, P. Reygagne, Johannes Wohlrab, M. Hertl, N. Fazel, E. Muscianisi, Heng Fan, I. Hampele, Nicolò Compagno   +13 more
semanticscholar   +1 more source

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

Therapeutic Advances in Musculoskeletal Disease, 2021
Background: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24.
Denis Poddubnyy, Effie Pournara, Agnieszka Zielińska, Asta Baranauskaite, Alejandro Muñoz Jiménez, Sanchayita Sadhu, Barbara Schulz, Michael Rissler, Chiara Perella, Helena Marzo-Ortega   +9 more
doaj   +1 more source

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies [PDF]

, 2016
The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. This review aimed to classify the available biologic agents and new small molecule inhibitors (licensed
Ciurtin, C, Elyoussfi, S, Thomas, BJ
core   +1 more source

Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials

Dermatologic Therapy
Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, we aim to summarize secukinumab safety in clinical trials (CTs) and post-marketing setting (PMS) until 25 June 2022. Adverse events (AEs)
Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark G. Lebwohl, A. Gottlieb, P. Mease, A. Deodhar, Weibin Bao, M. Mendelson, B. Porter, Deepa H Chand, Victor Dong   +11 more
semanticscholar   +1 more source

Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes

Frontiers in Microbiology, 2023
Introduction The role of gut microbiome dysbiosis in the pathogenesis of psoriasis has gained increasing attention in recent years. Secukinumab, targeting interleukin (IL)-17, has a promising efficacy in psoriasis treatment.
Xueshan Du, C. Yan, Shuzhen Kong, D. Che, B. Peng, Longfei Zhu, S. Geng, K. Guo   +7 more
semanticscholar   +1 more source

The Impact of Methotrexate on Cardiovascular Outcomes in Psoriasis: A Systematic Review and Meta‐Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa, Sheila T. K. Medorima, Renata F. Magalhães   +2 more
wiley   +1 more source

Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study

Frontiers in Medicine, 2022
Background: Secukinumab has been shown effective for psoriatic arthritis (PsA) and axial spondylarthritis (AxSpA) in randomized trials. The aim of this study was to analyze baseline patient and disease characteristics associated with a better retention ...
Alicia García-Dorta, Paola León-Suarez, Sonia Peña, Marta Hernández-Díaz, Carlos Rodríguez-Lozano, Enrique González-Dávila, María Vanesa Hernández-Hernández, Federico Díaz-González, Federico Díaz-González   +8 more
doaj   +1 more source

Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis [PDF]

, 2014
Parasitic worms are able to survive in their mammalian host for many years due to their ability to manipulate the immune response by secreting immunomodulatory products. It is increasingly clear that, reflecting the anti-inflammatory actions of such worm-
Al-Riyami, L., Harnett, M. M., Harnett, W., Pineda, M. A.   +3 more
core   +1 more source

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

Journal of dermatological treatment (Print)
Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.
M. Zhdanava, Timothy Fitzgerald, D. Pilon, Rachel E. Teneralli, Aditi Shah, Lilian Diaz, Patrick Lefebvre, Steven Feldman   +7 more
semanticscholar   +1 more source